SLNO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLNO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Soleno Therapeutics's Revenue per Share for the three months ended in Jun. 2024 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
For the Biotechnology subindustry, Soleno Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Soleno Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Soleno Therapeutics's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Soleno Therapeutics (NAS:SLNO) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Thank you for viewing the detailed overview of Soleno Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivo Opportunity Fund Holdings, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Bhatnagar Anish | director, officer: See Remarks | 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065 |
Kristen Yen | officer: See Remarks | 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065 |
Patricia C Hirano | officer: See Remarks | 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
James H Mackaness | officer: Chief Financial Officer | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Vivo Opportunity, Llc | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Abingworth Bioventures Vii Lp | 10 percent owner | PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Matthew Pauls | director | 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Llp Abingworth | 10 percent owner | 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Jack W Schuler | 10 percent owner | 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
Carlyle Holdings I L.p. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
Carlyle Holdings I Gp Sub L.l.c. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
From GuruFocus
By GuruFocus Research • 12-01-2023
By GlobeNewswire • 05-03-2024
By GuruFocus Research • 09-12-2024
By Marketwired • 05-22-2024
By Marketwired • 04-19-2024
By Marketwired • 04-30-2024
By Marketwired • 06-24-2024
By Marketwired • 08-27-2024
By Marketwired • 05-03-2024
By Marketwired • 05-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.